Evaluation of renoprotective and hypotensive effects by combined use of irbesartan and amlodipine besilate in elderly patients with hypertension.

Evaluation of renoprotective and hypotensive effects by combined use of irbesartan and amlodipine besilate in elderly patients with hypertension. - Evaluation of renoprotective and hypotensive effects by combined use of irbesartan and amlodipine besilate in elderly patients with hypertension.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008841

Enrollment

Registered

2012-09-03

Start date

2012-09-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

Irbesartan, Amlodipine besilate

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients with age of 75 years and more. 2)Male or female. 3)Outpatient or hospitalization. 4)Hypertension; Patient uses amlodipine or ARB for one month or more, In hospital, patient with systolic blood pressure of 140 mmHg and more, or diastolic blood pressure of 90 mmHg and more. In home, patient with systolic blood pressure of 135 mmHg and more, or diastolic blood pressure of 85 mmHg and more.

Exclusion criteria

Exclusion criteria: 1)Patients with hypersensitivity for the study drugs. 2)Patients with bilateral renal artery stenosis. 3)Patients with hyperkalemia. 4)Patients with eGFR value of 29 mL/min/1.73m2 or less. 5)Patients who uses of corticosteroid and/or immunosuppressant. 6)Patients who are considered to be inappropriate by the investigators.

Design outcomes

Primary

Measure	Time frame
Comparison of clinical and laboratory data before and after the start of combination therapy.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026